Bitwise Asset Management has increased its long-term Bitcoin price forecast to $1.6 million by 2036, driven by growing institutional demand, limited new Bitcoin supply, and Bitcoin's role as a store of value against currency debasement. The forecast assumes Bitcoin will capture 25% of a combined gold-and-Bitcoin store-of-value market projected to reach $109.8 trillion by 2036. Bitwise expects Bitcoin to outperform US equities and private equity with annualized returns of 34.3% over the next decade. Risks include regulatory changes, quantum computing, and AI advances, while institutional adoption and regulatory progress support the bullish outlook.
Bitcoin price forecasts are the subject, with Pluang market data providing context. For readers following major cryptocurrencies, 35 of 50 rose and 14 fell today on Pluang. Kusama (KSM) traded at Rp67.672 with a 1-day change of -2.34%, The Sandbox (SAND) at Rp875 with +2.31%, and Dogecoin (DOGE) at Rp1.443 with +2.27%, as of Oct 28, 2026 23:22 WIB.
On National First Responders Day, ADT celebrated local first responders and its monitoring professionals by unveiling a renovated monitoring center in Irving, Texas, part of a $2 million investment. The upgraded center features enhanced equipment and...
Cobalt Boats unveiled the 2027 265 Coastal Edition, a fully redesigned luxury outboard runabout tailored for coastal boating enthusiasts. Featuring wood-free construction, enhanced comfort, and advanced technology like dual 9-inch displays and option...
Presidio was named Enterprise Partner of the Year and Software and Services Partner of the Year for the Americas at the Cisco Partner Summit 2026. These awards recognize partners who excel in service and innovation, helping customers succeed through ...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
